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Abstract
Background: Sub-optimal maternal lipid levels during pregnancy may be implicated in the pathophysiological
mechanisms leading to low birth weight (LBW) and small-for-gestational-age (SGA). We aimed to determine
whether maternal lipid levels across pregnancy were associated with birth weight and the risks of LBW and SGA in
rural Gambia.
Methods: This secondary analysis of the ENID trial involved 573 pregnant women with term deliveries. Plasma
levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-
c), and triglycerides (TG) were analyzed at enrolment (mean (SD) = 13.9 (3.3) weeks gestation), 20 and 30 weeks
gestation as continuous variables and percentile groups. Regression models with adjustment for confounders were
used to examine associations between gestational lipid levels and birth weight and the risks of LBW (birth
weight < 2500 g) and SGA (<10th percentile INTERGROWTH-21ST for birth weight).
Results: There were 7.9% LBW and 32.5% SGA infants. At enrolment, every unit increase in HDL-c was associated
with a 2.7% (P = 0.011) reduction in relative risk of LBW. At 20 weeks gestation, every unit increase in TC levels was
associated with a 1.3% reduction in relative risk of LBW (P = 0.002). Low (<10th percentile) HDL-c at enrolment or at
20 weeks gestation was associated with a 2.6 (P = 0.007) and 3.0 (P = 0.003) times greater risk of LBW, respectively,
compared with referent (10th─90th) HDL-c. High (>90th percentile) LDL-c at 30 weeks gestation was associated
with a 55% lower risk of SGA compared with referent LDL-c (P = 0.017). Increased levels of TC (β = 1.3, P = 0.027) at
20 weeks gestation and of TC (β = 1.2, P = 0.006) and LDL-c (β = 1.5, P = 0.002) at 30 weeks gestation were all
associated with higher birth weight.
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Conclusions: In rural Gambia, lipid levels during pregnancy were associated with infant birth weight and the risks
of LBW and SGA. Associations varied by lipid class and changed across pregnancy, indicating an adaptive process
by which maternal lipids may influence fetal growth and birth outcomes.
Trial registration: This trial was registered as ISRCTN49285450 on: 12/11/2009.
Keywords: Maternal lipids, Cholesterol, Triglycerides, Birth weight, Low birth weight, Small-for-gestational-age,
Pregnancy, The Gambia
Background
Birth weight is a retrospective indicator of fetal growth and
maternal health during pregnancy, but also a subsequent
predictor of long-term health outcomes for both the mother
and her offspring [1–4]. Low birth weight (LBW) is defined
as a birth weight below 2500 g and small-for-gestational-age
(SGA) as a birth weight less than the 10th percentile for the
gestational age [1, 4–6]. In 2015, 20.5 million infants were
born LBW, representing 14.6% of all births [7]. Most (91%)
LBW infants were born in low- and middle-income coun-
tries (LMICs) with almost three-quarters in Asia and sub-
Saharan Africa [7]. It has been estimated that in 2012, one in
five infants from LMICs were born SGA, representing 23.3
million births in that year [8]. Both LBW and SGA are im-
portant indicators used to identify infants at greater risks of
morbidity and mortality [4]. LBW infants are about 20 times
more likely to die within the neonatal period compared to
those born with a normal birth weight (NBW; ≥2500 g) and
as a result, LBW is implicated in 60 to 80% of all neonatal
deaths [4, 9]. In a study conducted in Mozambique
(n = 5542), infants born SGA were found to have five times
higher rates of mortality compared to adequate-for-
gestational-age (AGA) infants [6].
Accumulating evidence indicates that imbalanced lipid
levels during pregnancy may alter fetal lipid metabolism,
thereby impacting fetal growth and birth weight, and the
metabolism of both the mother and her offspring [10–12].
During pregnancy, pronounced changes in lipid metabol-
ism occur characterized by an elevation of maternal lipids
to support the physiological adaptation to gestation and the
nutritional and hormonal needs of the gestating mother
and the growing fetus [13]. Maternal malnutrition, inflam-
mation or infection during pregnancy may lead to an inad-
equate response to pregnancy-induced changes in lipid
metabolism, abnormal maternal and fetal lipid levels and
adverse birth outcomes.
Previous investigations examining potential associations
between maternal lipid levels and birth weight have mostly
focused on the second trimester of pregnancy and have
often used lipid measurements from a single gestational
time-point. When compared to mid-range values, low total
cholesterol levels (TC) have been associated with lower
birth weight [12, 14] and greater risk of LBW [15], and high
TC [12, 16] or high triglycerides (TG) levels with higher
birth weight [12, 15–19]. In a case-control study conducted
in Canada, higher mean levels of high-density lipoprotein
(HDL) particles in the second trimester were found in
women with term-born SGA infants compared to women
with AGA infants [20]. In a population-based study from
China, high TG in the third trimester was found associated
with reduced risk of SGA [10].
Although LMICs carry the highest burden of LBW and
SGA cases, there is a paucity of data on the influence of
maternal gestational lipids on birth weight-related out-
comes in these settings which may hamper the develop-
ment of appropriate preventive, screening and prophylactic
interventions. The current study aimed to examine associa-
tions between maternal lipid levels across pregnancy with
birth weight and the risk of LBW and SGA in a cohort
from a food-insecure region of rural Gambia, in sub-
Saharan Africa.
Methods
Study population
This study is a secondary analysis of the Early Nutrition and
Immune Development (ENID) trial; ISRCTN49285450]), a
randomized, partially blinded trial investigating the impact
of prenatal and infancy nutritional supplementation on in-
fant development in the West Kiang region of The Gambia.
The published ENID trial protocol provides complete de-
tails of the trial [21] while an overview of relevant informa-
tion to the current secondary analysis is included here
(participant selection outlined in Fig. 1). All non-pregnant
women aged 18 to 45 years registered in the West Kiang
Demographic Surveillance System (DSS) were invited to
participate in the trial [22]. After written consent, all
women were visited monthly. Between January 2010 and
June 2013, 2798 women were recruited for monthly surveil-
lance of pregnancy. Women who missed their last menses
and had a positive urine pregnancy test were invited to the
Medical Research Council (MRC) Keneba clinic for an
ultrasound examination of pregnancy status and stage. Of
the 1195 women with a positive pregnancy test, those con-
firmed as pregnant but with a gestational age ≥ 20 weeks or
a multiple pregnancy or those confirmed as HIV positive or
with severe anemia (hemoglobin (Hb) < 7 g/dL) were ex-
cluded from the study. A total of 875 pregnant women who
met the inclusion criteria were randomized into the
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antenatal supplementation phase of the trial, yielding 800
live births. For the current analysis, 227 infants were ex-
cluded due to missing birth visit (n = 105) or birth weight
(n = 41) or not born at term with gestational age at delivery
below 37weeks or over 42 weeks (n = 81), resulting in 573
mother-newborn pairs (Fig. 1). Of note, preterm infants
were not included in this analysis due the low numbers of
preterm births within the ENID cohort (n = 14).
Intervention and procedures
The randomization procedure allocated eligible pregnant
women to one of four prenatal nutritional supplements; (i)
iron folic-acid (FeFol) tablets, the standard of care as per
Gambian Government guidelines; (ii) multiple micronutri-
ents (MMN) tablets, a combination of 22 micronutrients
designed for use during pregnancy by UNICEF/WHO/
UNU [23]; (iii) protein-energy and iron-folate (PE + FeFol),
a lipid-based nutritional supplement (LNS); and (iv)
protein-energy and multiple micronutrients (PE +MMN).
Supplement composition is described in Additional Table
A1. Field staff visited enrolled women weekly for supple-
ment provision. During weekly visits, compliance to supple-
ment was evaluated by an assessment of the quantity of
supplements not used, and a record of maternal morbidity
was also collected.
At enrolment (mean gestational (SD) = 13.9 (3.3) weeks
gestation), gestational age was assessed using a Siemens
ACUSON Antares Ultrasound Imaging System (Siemens
Medical Solutions USA, Inc., California, USA) with a CH6–
2 (5.71MHz) transducer). Further clinic visits were con-
ducted at 20 and 30weeks gestation. At all visits, data were
collected on maternal anthropometry, Hb, blood pressure,
and a urinary analysis was performed. A sample of venous
blood (10mL) was also collected following an overnight fast
and plasma samples were stored on ice until processing
within 1 h of collection. Standardized and validated equip-
ment and standard operating protocols were used and ap-
plied for all measurements. A study midwife visited women
and their newborns within 72 h of delivery for a standard
maternal and newborn health check. Infant weight and
Fig. 1 Flow chart of trial participants included in the analysis Abbreviations: LBW; low birth weight and SGA; small-for-gestational-age
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length were measured using digital infant scales (Seca mo-
bile digital baby-scale 334; UK) with 10 g precision and a
portable infant roll meter (Rollameter 100; Harlow Health-
care, UK) to the nearest 0.1 cm, respectively.
Laboratory analysis of maternal lipids
All maternal plasma samples were collected after an over-
night fast and analyzed in the MRC Keneba laboratory for
TC, HDL-c, low-density lipoprotein cholesterol (LDL-c),
and TG levels using enzymatic colorimetric assays with
Roche/Hitachi reagents and COBAS INTEGRA® 400 plus
analyzer (Roche Diagnostics, Indianapolis, IN). The few
samples that were physiologically aberrant, such as sam-
ples with detectable HDL-c and LDL-c levels but with a
TC level near zero, were excluded from the analysis.
Outcomes and cofactors
Low birth weight (LBW) was characterized as a birth
weight below 2500 g and compared to normal birth
weight (NBW) (≥2500 g) [9]. Small-for-gestational-age
(SGA) was defined as a birth weight-for-gestational-age
below the 10th percentile of the INTERGROWTH-21ST
standards for birth weight in comparison to adequate-
for-gestational (AGA) (≥10th percentile of the
INTERGROWTH-21ST standards for birth weight) [24].
The West Kiang DSS was used to verify mother's birth
date and age at enrolment [22]. A questionnaire col-
lected at enrolment was used to determine maternal par-
ity (i.e. numbers of stillbirths and live births). School
attendance was defined as a binary variable (yes/no)
based on whether enrolled women reported 1 year or
more of English or Arabic school and not as the number
of school years attended due to the low attendance mean
(SD) (0.31 (0.62) years). Maternal BMI was calculated as
weight (kg)/height (m)2 at each measurement time point
in gestation. Maternal gestational weight gain was calcu-
lated by subtracting maternal weight between; enrolment
and 20 weeks gestation, 20 and 30 weeks’ gestation, and
enrolment and 30 weeks gestation, and by dividing each
subtraction by the number of weeks between weight
measurements and expressed in kg/week. Maternal mor-
bidity was determined based on the number of self-
reports of morbidity episodes (e.g. fever, nausea/vomit-
ing, dysuria, bleeding and abdominal pain) assessed by
questionnaire and divided by the number of weeks en-
rolled in the trial (n/week). Compliance to supplementa-
tion from enrolment to delivery (%) was computed by
dividing the number of jars of LNS products (PE and
PE +MMN) (empty, half-empty, and full) or count of
tablets (MMN and FeFol) the women consumed by the
number received and multiplying by 100. Birth season of
the infant was defined as dry (November to May) or
rainy (June to October).
Statistical analyses
Maternal and infant variables were compared between
LBW and NBW infants, and between SGA and AGA in-
fants by Student’s t-test with Welch correction for un-
equal sample sizes. Unadjusted mean TC, HDL-c, LDL-c,
and TG levels at enrolment and 20 and 30 weeks’ gesta-
tion were calculated with 95% confidence intervals (95%
CI) and compared by Student’s t-test. Changes in mater-
nal lipid levels across gestation were examined using a
Wilcoxon rank-sum test for ordered groups and a paired
sample t-test. Maternal lipid levels were analyzed as con-
tinuous variables and grouped into low (<10th), referent
(10th–90th), and high (>90th) percentiles. Binary regres-
sion models were used to measure the relative risks (RR)
of LBW and SGA associated with maternal lipid levels in-
cluded as continuous or categorical variables (by percent-
ile groups). Reduction in relative risk (RRR) expressed as a
percentage was calculated as RRR%= (1-RR) × 100. The
RR values for the analyses of the risks of LBW and SGA
are presented in Additional Tables A2 and A3, respect-
ively. Linear regression models were used to investigate
associations between maternal lipids and birth weight (g)
as an outcome. Models were adjusted for confounding fac-
tors selected based on previous research and on whether
they significantly impacted on the models. For LBW and
birth weight outcomes these included enrolment maternal
age, parity, supplement groups (FeFol, MMN, PE or PE +
MMN), gestational age, BMI, Hb level at lipid measure-
ments, and compliance to supplement during pregnancy
and infant birth sex and birth season. For SGA, the same
confounding factors were used, but excluding gestational
age. A previous analysis of the ENID dataset has shown a
complex relationship between season and gestational
weight gain on birth outcomes [25]. Given the potential
relevance of changes in maternal BMI over pregnancy on
gestational lipid levels, we also fitted BMI and changes in
BMI within the models presented here. Statistical analyses
were conducted with Stata version 15 (StataCorp LP
Texas, USA).
Results
Cohort characteristics
A total of 573 pregnant women with singleton term in-
fants were included in this study. There were 45 (7.9%)
cases of LBW and 186 (32.5%) cases of SGA. At enrol-
ment, 20.6% of women were underweight (BMI < 18.5 kg/
m2), 68.2% were normal weight (BMI 18.5─24.9), 9.1%
were overweight (BMI 25─29.9) and 2.1% were obese
(BMI ≥ 30 kg/m2). Underweight women were significantly
more likely to have a LBW (12.7% vs 6.4%, P = 0.023) or
SGA (41.5% vs 29.7%, P = 0.014) infant compared to
women with a BMI > 18.5 kg/m2. Table 1 compares the
descriptive characteristics of the participants, split accord-
ing to LBW versus (vs) NBW and SGA vs AGA. Women
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with LBW infants were enrolled later in the trial, were
more likely to be nulliparous, had lower gestational age at
delivery, a lower BMI at all time points of gestation and a
lower gestational weight gain between enrolment (mean
gestational (SD) = 13.9 (3.3) weeks gestation) and 20 weeks
gestation compared with women with NBW infants (all,
Table 1 Comparison of participants characteristics (n = 573) by LBW and SGA infant statusa
Variablesb LBW (n = 45) NBW (n = 528) p-valuec SGA (n = 186) AGA (n = 387) p-valuec
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Maternal variables
Enrolmentd
Gestational age (weeks) 14.9 (3.4) 13.8 (3.29) 0.034 14.1 (2.9) 13.8 (3.5) 0.249
Age (years) 29.2 (7.3) 30.4 (6.5) 0.274 30.3 (6.7) 30.3 (6.5) 0.888
Parity (n) 3.5 (2.7) 4.3 (2.6) 0.072 4.1 (2.7) 4.3 (2.5) 0.504
Nulliparous, n (%) 9 (20.0) 40 (7.7) 0.005 39 (8.1) 10 (12.1) 0.242
Educated, n (%) 7 (15.9) 114 (22.0) 0.348 38 (20.8) 83 (21.8) 0.711
Hb (g/L) 11.4 (1.5) 11.3 (1.4) 0.823 11.3 (1.5) 11.4 (1.3) 0.619
Supplement group, n (%) 0.916e 0.323e
FeFol 10 (22.2) 123 (23.3) 48 (25.8) 85 (22.0)
MMN 13 (28.9) 143 (27.1) 49 (26.3) 107 (27.7)
PE 10 (22.2) 129 (24.4) 46 (24.7) 93 (24.0)
PE + MMN 12 (26.7) 133 (25.2) 43 (23.1) 102 (26.4)
BMI (kg/m2) 19.7 (3.1) 21.1 (3.4) 0.008 20.3 (3.0) 21.3 (3.5) 0.001
BMI group), n (%) 0.032e 0.012e
Underweight (< 18.5 kg/m2) 15 (34.1) 103 (19.6) 49 (26.8) 69 (17.9)
Normal weight (18.5─24.9 kg/m2) 26 (59.1) 365 (69.5) 119 (65.0) 272 (70.5)
Overweight (≥25 kg/m2) 3 (6.8) 57 (10.9) 15 (8.2) 45 (11.7)
Weight gain (enrolment to 20 weeks) (kg/week) 0.28 (0.30) 0.38 (0.35) 0.048 0.34 (0.31) 0.39 (0.37) 0.062
20 weeks gestation
Hb (g/dL) 10.7 (1.3) 10.9 (1.15) 0.435 10.8 (1.2) 10.9 (1.1) 0.382
BMI (kg/m2) 20.8 (3.0) 22.0 (3.2) 0.010 21.1 (2.8) 22.3 (3.3) < 0.001
Weight gain (20 to 30 weeks) (kg/week) 0.30 (0.16) 0.30 (0.21) 0.986 0.29 (0.18) 0.31 (0.22) 0.256
30 weeks gestation
Hb (g/dL) 10.7 (1.4) 10.6 (1.3) 0.501 10.7 (1.4) 10.6 (1.3) 0.320
BMI (kg/m2) 21.9 (3.0) 23.1 (3.1) 0.014 22.2 (2.7) 23.4 (3.2) < 0.001
Weight gain (enrolment to 30 weeks) (kg/week) 0.30 (0.13) 0.33 (0.18) 0.260 0.30 (0.15) 0.34 (0.19) 0.028
Across pregnancy
Morbidity episodes (n/week) 0.18 (0.25) 0.20 (0.24) 0.694 0.17 (0.19) 0.20 (0.26) 0.117
Compliance to nutritional supplement (%)f 87.6 (9.8) 87.3 (14.4) 0.839 88.0 (12.6) 87.0 (14.7) 0.393
Gestational age at delivery (weeks) 39.5 (1.1) 40.2 (0.97) < 0.001 40.3 (1.0) 40.1 (0.97) 0.012
Infant variables
Sex, n (%): Female 31 (68.9) 261 (49.4) 0.012 92 (49.5) 200 (51.7) 0.619
Birth season, n (%): dry (Nov-May) 33 (73.3) 322 (61.0) 0.101 122 (65.6) 233 (60.2) 0.214
aThe total sample comprised 573 mother-infant pairs and was compared according to LBW (< 2.5 kg) versus NBW (≥2.5 kg) and SGA (<10th percentile
INTERGROWTH-21ST for birth weight) vs AGA (≥10th percentile INTERGROWTH-21ST for birth weight) and each comparison included the total sample (n = 573)
bValues are means with standard deviation (SD) unless otherwise specified
cP-values were calculated from Student’s t-test with Welch correction for unequal sample sizes by comparing LBW to NBW groups and SGA to AGA groups
dMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
eP-values were calculated by ANOVA
fCompliance to supplement was calculated by dividing the number of jars or tablets the women consumed by the number she received and multiplying by 100
Abbreviations: AGA adequate-for-gestational-age, BMI body mass index, FeFol iron and folic acid, Hb hemoglobin, LBW low birth weight, MMN multiple
micronutrient, NBW normal birth weight, PE protein energy, SGA small-for-gestational-age
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P < 0.05). LBW infants were all born SGA and were more
likely to be female (P = 0.012). Women with SGA infants
also had a lower BMI at all gestational time points (all,
P < 0.01), a lower gestational weight gain between enrol-
ment and 30 weeks gestation (P = 0.028) and higher gesta-
tional age at delivery (P = 0.012) compared with women
with AGA infants. SGA infants were more likely to be
born with a normal birth weight than with a LBW (75.8%
vs 24.2%, P < 0.001). There were no significant differences
in risk of LBW or SGA by maternal nutritional supple-
ment group.
Changes in maternal lipid levels across pregnancy
Mean levels of TC, LDL-c and TG increased from enrol-
ment to 30 weeks gestation (all, P < 0.001) while mean
HDL-c levels increased slightly from enrolment to 20weeks
gestation (51.4 vs 53.1mg/dL, P = 0.003) before decreasing
back, by 30weeks gestation, to similar levels observed at en-
rolment (53.1 vs 51.2mg/dL, P < 0.001). Longitudinal
changes in maternal lipid levels were compared by LBW vs
NBW and SGA vs AGA (Fig. 2). Women with LBW infants
had lower mean TC levels at 20 weeks gestation compared
to those with NBW infants (133.6 vs 149.6mg/dL, P =
0.048) (Fig. 2a). Women with SGA infants had lower mean
LDL-c (99.5 vs 105.9mg/dL, P = 0.033), and TG (94.2 vs
99.4mg/dL, P = 0.048) levels at 30 weeks gestation com-
pared to women with AGA infants (Fig. 2b).
Links between maternal lipid levels during pregnancy
and the risk of delivering a LBW infant were investigated
using regression models (Table 2 and Table 3). In the
adjusted analyses, every unit increase in HDL-c at enrol-
ment was associated with a 2.7% (P = 0.011) reduction in
the relative risk of LBW and every unit increase in TC
levels at 20 weeks gestation were associated with a 1.3%
reduction in the relative risk of LBW (P = 0.002)
(Table 2). Women with low (<10th percentile) HDL-c at
enrolment or at 20 weeks gestation had a 2.6 (P = 0.007)
and 3.0 (P = 0.003) higher risk of delivering a LBW
Fig. 2 Mean maternal plasma lipids at enrolment, 20 and 30 weeks gestation by LBW and SGA status. Mean maternal lipids were compared by
Student’s t-test with Welch correction for unequal sample size between low birth weight (LBW) (< 2.5 kg) and normal birth weight infant (NBW)
(≥2.5 kg) and between small-for-gestational-age (SGA) (<10th percentile INTERGROWTH-21ST for birth weight) and adequate-for-gestational-age
(AGA) (≥10th percentile INTERGROWTH-21ST for birth weight) infants. Mean total cholesterol (TC) levels were significantly lower at 20 weeks
gestation in women with LBW infants compared to women with NBW infants (P = 0.048). Women with SGA infants had at 30 weeks gestation
lower mean low-density lipoprotein cholesterol (LDL-c) (P = 0.033) and triglycerides (TG) (P = 0.048) levels compared to women with AGA infants.
Mean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
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infant compared to women with referent (10th─90th
percentile) HDL-c level, respectively (Table 3).
Tables 4 and 5 present associations between maternal
lipid levels and risk of SGA. In the unadjusted analyses,
an association between increased LDL-c levels at 30
weeks gestation and a reduced risk of SGA was detected
(RRR = 0.38%, P = 0.048) (Table 4) but no other associa-
tions were observed. In both the unadjusted and ad-
justed analyses, women with high (>90th percentile)
LDL-c at 30 weeks gestation had a 55% (P = 0.017) lower
risk of delivering an SGA infant compared to women
with referent (10th─90th percentile) LDL-c levels
(Table 5). In the unadjusted analyses, women with high
(>90th percentile) TG at 30 weeks gestation had a 48%
(P = 0.035) lower risk of delivering an SGA infant com-
pared to women with referent (10th─90th percentile)
TG, however, this association was lost following adjust-
ment for confounding factors (Table 5).
Linear regression models were used to examine associ-
ations between maternal lipid levels during pregnancy
and birth weight (Table 6 and Table 7). In the un-
adjusted analyses, increased levels of TC and LDL-c at
20 and 30 weeks gestation and of TG at 30 weeks gesta-
tion were all associated with a higher infant birth weight
(all, P < 0.05) (Table 6). After adjustment with confound-
ing factors, only increased levels of TC at 20 weeks ges-
tation (β = 1.3, P = 0.027) and of TC (β = 1.2, P = 0.006)
and LDLc (β = 1.5, P = 0.002) at 30 weeks gestation
remained associated with a higher birth weight (Table 6).
In both the unadjusted and adjusted analyses, women
with high (>90th percentile) levels of TC, LDL-c or TG
at 30 weeks gestation had infants with higher birth
weights compared with women with referent
(10th─90th percentile) levels (P < 0.05) (Table 7).
In a sub-analysis, we explored potential interactions be-
tween maternal nutritional supplement groups, BMI, lipid
levels and infant birth weight outcomes (Additional Tables
A4 to A8). Associations were observed between maternal
nutritional supplement groups and maternal lipid levels
during pregnancy (Table A4). Compared to FeFol (referent/
control group), supplementation with PE +MMN was asso-
ciated with lower HDLc levels at 20 (β = − 3.7, P = 0.028)
and 30 (β = − 4.3, P = 0.013) weeks gestation, and supple-
mentation with PE was associated with higher LDL-c levels
(β = 9.3, P = 0.034) at 30 weeks gestation (Table A4). We
also detected associations between maternal lipid levels and
BMI during pregnancy (Table A5). At enrolment, a lower
BMI was associated with increased HDL-c levels (β = −
0.025, P = 0.021) whereas a higher BMI was associated with
increased LDL-c levels (β = 0.012, P = 0.034). At 20 and 30
weeks gestation, higher BMIs were linked to increased TG
levels (β = 0.011, P = 0.018 and β = 0.009, P = 0.048, respect-
ively) (Table A5). However, there were no associations be-
tween maternal nutritional supplement groups and
Table 2 Relative risk reduction (RRR) (%) (95% CI) of LBW in association with maternal total, HDL and LDL cholesterol and
triglycerides levels at enrolment, 20 and 30 weeks gestationa
Gestation week RRR (%) (95% CI) p-value aRRR (95% CI)b p-value
Total cholesterol
Enrolmentc 0.02 (−0.66, 0.70) 0.944 0.51 (−0.27, 1.3) 0.196
20 weeks 1.1 (0.02, 2.2) 0.045 1.3 (0.49, 2.2) 0.002
30 weeks 0.31 (− 0.28, 0.89) 0.302 0.30 (− 0.39, 0.98) 0.399
HDL cholesterol
Enrolmentc 1.9 (−0.10, 3.9) 0.063 2.7 (0.64, 4.8) 0.011
20 weeks 2.4 (−0.57, 5.3) 0.112 2.7 (−0.59, 6.0) 0.106
30 weeks 1.1 (−0.95, 3.0) 0.300 0.27 (−1.5, 2.0) 0.763
LDL cholesterol
Enrolmentc −0.23 (−1.1, 0.59) 0.581 −0.01 (− 0.96, 0.92) 0.977
20 weeks 0.66 (− 0.33, 1.6) 0.190 1.0 (− 0.04, 2.1) 0.060
30 weeks 0.23 (−0.41, 0.86) 0.486 0.33 (−0.39, 1.1) 0.370
Triglycerides
Enrolmentc −0.52 (−1.5, 0.49) 0.316 0.02 (−1.2, 1.2) 0.977
20 weeks −0.19 (−1.6, 1.2) 0.792 −0.45 (−2.0, 1.1) 0.560
30 weeks 0.41 (−0.40, 1.2) 0.320 0.33 (−0.50, 1.2) 0.436
aRelative risk reduction was calculated as % = (1 - RR) × 100. The RR values are presented in additional Table A2
bBinary regression models were adjusted with enrolment maternal age, parity, gestational age, hemoglobin concentration, BMI, supplement group, and
compliance to supplement during pregnancy, and infant birth sex and birth season
cMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein, (a)RRR adjusted relative risk reduction
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Table 3 Relative risk (RR) (95% CI) of LBW by maternal total, HDL and LDL cholesterol and triglycerides levels divided in percentile
groups, at enrolment, 20 and 30 weeks gestationa
Gestation week mg/dL LBW, n (%) Unadjusted Adjustedb
RR (95%CI) p-value aRR (95%CI) p-value
Total cholesterol
Enrolmentc
Low (<10th) < 88.6 2 (4.1) 0.42 (0.10, 1.7) 0.221 0.54 (0.14, 2.2) 0.384
Ref (10th─90th) 88.6─170.5 38 (9.7) Ref Ref
High (>90th) > 170.5 1 (2.0) 0.21 (0.03, 1.5) 0.119 0.17 (0.02, 1.2) 0.070
20 weeks
Low (<10th) < 112.9 3 (7.1) 0.90 (0.29, 2.9) 0.865 1.2 (0.78, 1.8) 0.451
Ref (10th─90th) 112.9─185.6 27 (7.9) Ref Ref
High (>90th) > 185.6 0 (0.0) – – – –
30 weeks
Low (<10th) < 123.6 2 (4.1) 0.41 (0.10, 1.6) 0.195 0.38 (0.09, 1.6) 0.197
Ref (10th─90th) 123.6─214.2 40 (10.2) Ref Ref
High (>90th) > 214.2 1 (2.0) 0.20 (0.03, 1.4) 0.103 0.20 (0.03, 1.6) 0.139
HDL cholesterol
Enrolmentc
Low (<10th) < 33.6 7 (13) 1.6 (0.74, 3.4) 0.229 2.6 (1.3, 5.3) 0.007
Ref (10th─90th) 33.6─68.4 34 (8.1) Ref Ref
High (>90th) > 68.4 2 (3.8) 0.47 (0.11, 1.9) 0.283 0.50 (0.12, 2.1) 0.337
20 weeks
Low (<10th) < 36.3 6 (12.8) 2.0 (0.85, 4.6) 0.115 3.0 (1.5, 6.4) 0.003
Ref (10th─90th) 36.3─70 24 (6.5) Ref Ref
High (>90th) > 70 1 (2.1) 0.30 (0.05, 2.4) 0.270 0.40 (0.07, 2.6) 0.341
30 weeks
Low (<10th) < 33.3 6 (11.5) 1.3 (0.58, 3.0) 0.507 0.90 (0.37, 2.2) 0.813
Ref (10th─90th) 33.3─ 68.4 35 (8.8) Ref Ref
High (>90th) > 68.4 4 (7.3) 0.80 (0.31, 2.3) 0.716 0.90 (0.41, 1.9) 0.753
LDL cholesterol
Enrolmentc
Low (<10th) < 43.3 3 (5.1) 0.58 (0.19, 1.8) 0.357 0.63 (0.21, 1.8) 0.390
Ref (10th─90th) 43.3─106 36 (8.7) Ref Ref
High (>90th) > 106 4 (7.4) 0.85 (0.31, 2.3) 0.748 0.68 (0.24, 1.9) 0.467
20 weeks
Low (<10th) < 53.4 1 (2.2) 0.28 (0.04, 2.0) 0.203 0.44 (0.10, 2.0) 0.280
Ref (10th─90th) 53.4─122.6 29 (7.8) Ref Ref
High (>90th) > 122.6 1 (2.1) 0.30 (0.04, 2.0) 0.196 0.30 (0.04, 2.2) 0.229
30 weeks
Low (<10th) < 62.3 2 (3.9) 0.37 (0.09, 1.5) 0.159 0.42 (0.10, 1.7) 0.229
Ref (10th─90th) 62.3─146.6 43 (10.6) Ref Ref
High (>90th) > 146.6 0 (0.0) – – – –
Triglycerides
Enrolmentc
Low (<10th) < 35.4 1 (2) 0.23 (0.03, 1.7) 0.147 0.26 (0.03, 2.0) 0.193
Ref (10th─90th) 35.4─88.6 37 (8.7) Ref Ref
High (>90th) > 88.6 5 (9.3) 1.1 (0.44, 2.6) 0.896 0.97 (0.42, 2.2) 0.937
20 weeks
Low (<10th) < 53.1 3 (5.3) 0.70 (0.22, 2.2) 0.553 0.94 (0.28, 3.2) 0.926
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maternal BMI at any timepoint across pregnancy (Table
A6). Additionally, maternal supplement groups were not as-
sociated with the risks of LBW or SGA (Table A7) or birth
weight (Table A8).
Discussion
In this cohort of pregnant women from rural Gambia,
plasma lipid levels were lower compared to those reported
in studies from high-income countries [26–29] or urban
areas in LMICs [30], likely reflecting the typical diet in
rural Gambia which is low in animal-source foods and
consists mainly of carbohydrate-rich staple foods. Low
HDL-c levels in the first half of pregnancy were associated
with three times the risk of LBW. Increased TC levels
from mid-pregnancy were associated with higher birth
weight and high LDL-c at 30 weeks gestation was associ-
ated with half the risk of SGA. These findings suggest that
dietary interventions to improve diet and increase choles-
terol levels during pregnancy may promote fetal growth
and reduce adverse birth weight-related outcomes.
Table 3 Relative risk (RR) (95% CI) of LBW by maternal total, HDL and LDL cholesterol and triglycerides levels divided in percentile
groups, at enrolment, 20 and 30 weeks gestationa (Continued)
Gestation week mg/dL LBW, n (%) Unadjusted Adjustedb
RR (95%CI) p-value aRR (95%CI) p-value
Ref (10th─90th) 53.1─112.5 27 (7.5) Ref Ref
High (>90th) > 112.5 2 (4.3) 0.60 (0.10, 2.3) 0.432 0.60 (0.20, 2.7) 0.539
30 weeks
Low (<10th) < 65.5 2 (4.2) 0.41 (0.10, 1.6) 0.203 0.44 (0.11, 1.7) 0.233
Ref (10th─90th) 65.5─134.6 42 (10.3) Ref Ref
High (>90th) > 134.6 1 (2.0) 0.20 (0.03, 1.4) 0.098 0.20 (0.02, 1.5) 0.116
aBinary regression models between the risk of LBW and maternal lipid levels divided by percentile groups; <10th percentile (low), 10th─90th
(reference, Ref), >90th percentile (high)
bAdjusted relative risk (aRR) with enrolment maternal age, parity, gestational age, hemoglobin concentration, BMI, supplement group, and
compliance to supplement during pregnancy, and infant birth sex and birth season
cMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein, LBW low birth weight, (a)RR adjusted relative risk
Table 4 Relative risk reduction (RRR) (%) (95%CI) of SGA in association with maternal total, HDL and LDL cholesterol and
triglycerides levels at enrolment, 20 and 30 weeks gestationa
Gestation week RRR (%) (95% CI) p-value aRRR (95% CI)b p-value
Total cholesterol
Enrolmentc 0.13 (−0.24, 0.51) 0.489 0.11 (−0.28, 0.5) 0.576
20 weeks 0.18 (−0.30, 0.65) 0.463 −0.01 (− 0.49, 0.47) 0.975
30 weeks 0.29 (− 0.06, 0.63) 0.101 0.16 (− 0.21, 0.52) 0.395
HDL cholesterol
Enrolmentc 0.05 (−0.83, 0.92) 0.919 0.32 (−0.63, 1.3) 0.507
20 weeks −0.04 (−1.2, 1.1) 0.947 0.15 (−1.1, 1.3) 0.808
30 weeks 0.02 (−0.93, 0.96) 0.968 −0.08 (−1.01, 0.85) 0.873
LDL cholesterol
Enrolmentc 0.12 (−0.33, 0.57) 0.604 0.00 (−0.45, 0.45) 0.991
20 weeks 0.09 (−0.42, 0.61) 0.723 −0.07 (− 0.60, 0.45) 0.785
30 weeks 0.38 (0.00, 0.76) 0.048 0.26 (−0.13, 0.65) 0.193
Triglycerides
Enrolmentc 0.13 (−0.43, 0.69) 0.640 0.11 (−0.49, 0.69) 0.725
20 weeks 0.33 (−0.25, 0.91) 0.261 0.19 (−0.38, 0.75) 0.514
30 weeks 0.42 (−0.03, 0.87) 0.068 0.32 (−0.14, 0.77) 0.168
aRelative risk reduction was calculated as % = (1 - RR) × 100. The RR values are presented in additional Table A3
bBinary regression models were adjusted with enrolment maternal age, parity, hemoglobin concentration, BMI, supplement group, and compliance to supplement
during pregnancy, and infant birth sex and birth season
cMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein, (a)RRR adjusted relative risk reduction, SGA small-for-gestational-age
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Table 5 Relative risk (RR) (95% CI) of SGA by maternal total, HDL and LDL cholesterol and triglycerides levels divided in percentile
groups, at enrolment, 20 and 30 weeks gestationa
Gestation week mg/dL SGA, n (%) Unadjusted Adjustedb
RR (95%CI) p-value aRR (95%CI) p-value
Total cholesterol
Enrolmentc
Low (<10th) < 88.6 13 (26.5) 0.78 (0.48, 1.3) 0.312 0.82 (0.51, 1.3) 0.422
Ref (10th─90th) 88.6─170.5 133 (34.1) Ref Ref
High (>90th) > 170.5 11 (22.5) 0.66 (0.38, 1.1) 0.128 0.73 (0.42, 1.2) 0.246
20 weeks
Low (<10th) < 112.9 16 (38.1) 1.2 (0.79, 1.8) 0.401 1.1 (0.69, 1.8) 0.672
Ref (10th─90th) 112.9─185.6 109 (31.9) Ref Ref
High (>90th) > 185.6 11 (25.6) 0.80 (0.47, 1.4) 0.419 0.86 (0.51, 1.5) 0.576
30 weeks
Low (<10th) < 123.6 15 (30.6) 0.93 (0.59, 1.4) 0.742 0.82 (0.51, 1.3) 0.427
Ref (10th─90th) 123.6─214.2 129 (33) Ref Ref
High (>90th) > 214.2 10 (20) 0.61 (0.34, 1.1) 0.087 0.65 (0.36, 1.2) 0.142
HDL cholesterol
Enrolmentc
Low (<10th) < 33.6 18 (33.3) 1.0 (0.67, 1.5) 0.981 1.2 (0.82, 1.7) 0.352
Ref (10th─90th) 33.6─68.4 139 (33.2) Ref Ref
High (>90th) > 68.4 15 (28.3) 0.85 (0.54, 1.3) 0.489 0.82 (0.50, 1.4) 0.443
20 weeks
Low (<10th) < 36.3 19 (40.4) 1.4 (0.95, 2.0) 0.095 1.7 (1.3, 2.3) 0.052
Ref (10th─90th) 36.3─70 108 (29.2) Ref Ref
High (>90th) > 70 16 (34) 1.2 (0.76, 1.8) 0.482 1.2 (0.81, 1.9) 0.312
30 weeks
Low (<10th) < 33.3 15 (28.9) 0.88 (0.56, 1.4) 0.580 0.80 (0.51, 1.3) 0.337
Ref (10th─90th) 33.3─ 68.4 131 (32.8) Ref Ref
High (>90th) > 68.4 17 (30.9) 0.94 (0.62, 1.4) 0.787 0.88 (0.57, 1.3) 0.543
LDL cholesterol
Enrolmentc
Low (<10th) < 43.3 18 (30.5) 0.92 (0.61, 1.4) 0.688 0.89 (0.59, 1.4) 0.601
Ref (10th─90th) 43.3─106 137 (33.2) Ref Ref
High (>90th) > 106 17 (31.5) 0.95 (0.63, 1.4) 0.806 1.0 (0.66, 1.5) 0.991
20 weeks
Low (<10th) < 53.4 15 (32.6) 1.1 (0.69, 1.7) 0.733 1.05 (0.65, 1.7) 0.851
Ref (10th─90th) 53.4─122.6 112 (30.2) Ref Ref
High (>90th) > 122.6 16 (34) 1.1 (0.74, 1.7) 0.582 1.3 (0.84, 1.9) 0.265
30 weeks
Low (<10th) < 62.3 18 (35.3) 1.0 (0.70, 1.5) 0.843 0.86 (0.54, 1.4) 0.543
Ref (10th─90th) 62.3─146.6 137 (33.9) Ref Ref
High (>90th) > 146.6 8 (15.4) 0.45 (0.24, 0.90) 0.018 0.45 (0.23, 0.90) 0.017
Triglycerides
Enrolmentc
Low (<10th) < 35.4 12 (24.5) 0.73 (0.44, 1.2) 0.229 0.70 (0.42, 1.2) 0.181
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Consistent with previous studies, we observed an in-
crease in plasma TC, LDL-c and TG levels across preg-
nancy [10, 16, 17, 26, 27], which is known to be part of a
normal physiological response to gestation [28]. How-
ever, unlike in studies from higher-income countries [10,
27, 28], our data show a decrease in HDL-c levels from
20 to 30 weeks gestation, following an initial rise across
the first half of pregnancy. Similarly, a study conducted
in rural India (n = 631) reported a decrease in maternal
HDL-c levels between 18 and 28 weeks gestation [16].
These observations indicate that dietary intake may in-
fluence changes in HDL-c level across pregnancy and
Table 5 Relative risk (RR) (95% CI) of SGA by maternal total, HDL and LDL cholesterol and triglycerides levels divided in percentile
groups, at enrolment, 20 and 30 weeks gestationa (Continued)
Gestation week mg/dL SGA, n (%) Unadjusted Adjustedb
RR (95%CI) p-value aRR (95%CI) p-value
Ref (10th─90th) 35.4─88.6 142 (33.5) Ref Ref
High (>90th) > 88.6 18 (33.3) 1.0 (0.67, 1.5) 0.982 0.95 (0.62, 1.5) 0.798
20 weeks
Low (<10th) < 53.1 20 (35.1) 1.1 (0.74, 1.6) 0.653 1.1 (0.75, 1.6) 0.649
Ref (10th─90th) 53.1─112.5 116 (32.1) Ref Ref
High (>90th) > 112.5 9 (19.2) 0.60 (0.30, 1.1) 0.095 0.70 (0.40, 1.2) 0.195
30 weeks
Low (<10th) < 65.5 15 (31.3) 0.92 (0.59, 1.4) 0.709 0.83 (0.53, 1.3) 0.444
Ref (10th─90th) 65.5─134.6 139 (34) Ref Ref
High (>90th) > 134.6 9 (17.7) 0.52 (0.28, 0.99) 0.035 0.54 (0.29, 1.0) 0.068
aBinary regression models between the risk of SGA and maternal lipid levels divided by percentile groups; <10th percentile (low), 10th─90th (reference, Ref),
>90th percentile (high)
bAdjusted relative risk were adjusted with enrolment maternal age, parity, hemoglobin concentration, BMI, supplement group, and compliance to supplement
during pregnancy, and infant birth sex and birth season
cMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein, (a)RRR adjusted relative risk reduction, SGA small-for-gestational-age
Table 6 Beta coefficients (95% CI) for maternal total, HDL and LDL cholesterol and triglycerides levels, at enrolment, 20 and 30
weeks gestation, in association with birth weight in grams
Gestation week Unadjusted Adjusteda
R2 β (95% CI) p-value R2 β (95% CI) p-value
Total cholesterol
Enrolmentb 0.012 0.90 (−0.01, 1.9) 0.052 0.152 1.1 (− 0.01, 2.2) 0.053
20 weeks 0.010 1.3 (0.20, 2.4) 0.026 0.130 1.3 (0.20, 2.5) 0.027
30 weeks 0.012 1.1 (0.30, 1.9) 0.006 0.098 1.2 (0.30, 2.0) 0.006
HDL cholesterol
Enrolmentb 0.002 0.10 (−2.2, 2.4) 0.933 0.140 0.66 (−2.0, 3.3) 0.621
20 weeks 0.001 1.0 (−1.5, 3.6) 0.427 0.113 1.5 (−1.3, 4.2) 0.295
30 weeks 0.001 0.80 (− 1.5, 3.0) 0.500 0.086 0.90 (−1.5, 3.3) 0.457
LDL cholesterol
Enrolmentb 0.009 1.0 (−0.10, 2.2) 0.080 0.142 0.80 (− 0.40, 2.1) 0.206
20 weeks 0.009 1.3 (0.10, 2.5) 0.033 0.119 1.1 (−0.10, 2.4) 0.082
30 weeks 0.018 1.5 (0.60, 2.4) 0.001 0.104 1.5 (0.50, 2.4) 0.002
Triglycerides
Enrolmentb 0.003 0.40 (−1.1, 2.0) 0.589 0.139 0.80 (− 1.0, 2.7) 0.385
20 weeks 0.002 0.70 (−0.60, 2.1) 0.292 0.119 0.50 (−1.0, 2.0) 0.511
30 weeks 0.007 1.1 (0.10, 2.1) 0.039 0.093 1.0 (−0.10, 2.1) 0.068
aLinear regression models were adjusted with maternal age, parity, gestational age, hemoglobin concentration, BMI, supplement group, and compliance to
supplement during pregnancy, and infant birth sex and birth season
bMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein
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Table 7 Mean differences in birth weight by percentile groups of maternal total, HDL and LDL cholesterol and triglycerides levels, at
enrolment, 20 and 30 weeks gestationa
Gestation week mg/dL N Unadjusted Adjustedb
Mean difference (95% CI)
in birth weight (g)
p-value Mean difference (95% CI)
in birth weight (g)
p-value
Total cholesterol
Enrolmentc
Low (<10th) < 88.6 49 3.2 (− 108.4, 114.8) 0.955 4.1 (− 109.3, 117.4) 0.944
Ref (10th─90th) 88.6─170.5 390 Ref Ref
High (>90th) > 170.5 49 62.6 (−45.7, 170.9) 0.257 33.0 (−80.8, 146.9) 0.569
20 weeks
Low (<10th) < 112.9 42 −21.0 (− 131.2, 89.2) 0.708 −31.3 (− 142.3, 79.7) 0.580
Ref (10th─90th) 112.9─185.6 342 Ref Ref
High (>90th) > 185.6 43 109.8 (−1.2, 220.8) 0.052 110.1 (−9.1, 229.3) 0.070
30 weeks
Low (<10th) < 123.6 49 −51.2 (−130.1, 27.7) 0.203 −45.3 (− 126.0, 35.4) 0.270
Ref (10th─90th) 123.6─214.2 391 Ref Ref
High (>90th) > 214.2 50 108.9 (11.7, 206.1) 0.028 111.2 (9.0, 213.3) 0.033
HDL cholesterol
Enrolmentc
Low (<10th) < 33.6 54 −11.9 (−130.9, 107.2) 0.845 −42.1 (− 164.2, 79.9) 0.498
Ref (10th─90th) 33.6─68.4 419 Ref Ref
High (>90th) > 68.4 53 37.1 (−66.9, 141.2) 0.484 37.8 (−73.4, 149.1) 0.504
20 weeks
Low (<10th) < 36.3 47 −55.0 (− 171.5, 61.5) 0.354 −100.5 (−214.3, 13.4) 0.084
Ref (10th─90th) 36.3─70 370 Ref Ref
High (>90th) > 70 47 −2.5 (− 100.4, 95.5) 0.961 −6.4 (−116.8, 104.0) 0.909
30 weeks
Low (<10th) < 33.3 52 −31.5 (−133.5, 70.5) 0.544 −14.8 (− 121.2, 91.5) 0.784
Ref (10th─90th) 33.3─ 68.4 400 Ref Ref
High (>90th) > 68.4 55 −9.0 (− 118.2, 100.1) 0.871 5.7 (−103.1, 114.5) 0.918
LDL cholesterol
Enrolmentc
Low (<10th) < 43.3 59 2.7 (−101.3, 106.7) 0.959 5.2 (−95.1, 105.4) 0.919
Ref (10th─90th) 43.3─106 413 Ref Ref
High (>90th) > 106 54 −6.6 (−114.6, 101.5) 0.905 −27.7 (−139.1, 83.7) 0.626
20 weeks
Low (<10th) < 53.4 46 −15.4 (− 123.8, 93.0) 0.780 −9.3 (− 119.9, 101.3) 0.868
Ref (10th─90th) 53.4─122.6 371 Ref Ref
High (>90th) > 122.6 47 42.1 (−67.3, 151.4) 0.450 24.2 (−93.8, 142.3) 0.687
30 weeks Ref
Low (<10th) < 62.3 51 −51.9 (−141.1, 37.3) 0.254 −54.3 (− 153.1, 44.6) 0.281
Ref (10th─90th) 62.3─146.6 404 Ref Ref
High (>90th) > 146.6 52 122.1 (30.8, 213.4) 0.009 125.3 (29.7, 220.8) 0.010
Triglycerides
Enrolmentc
Low (<10th) < 35.4 49 87.4 (−27.6, 202.5) 0.136 92.6 (−22.3, 207.5) 0.114
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specifically the ability to maintain HDL-c levels in the
latter part of gestation.
In line with previous research from a range of settings,
relationships between maternal TC, HDL-c, LDL-c, and
TG levels during pregnancy and size at birth were ob-
served in our study. An association between increased
TC levels at 20 weeks gestation and a reduced risk of
LBW was detected and increased TC levels at both 20
and 30 weeks’ gestation were associated with higher
birth weight. In a study conducted in Nigeria (n = 261),
women with low TC in early pregnancy had a 2-fold in-
creased risk of delivering an LBW infant compared to
women with TC levels within the mid-range [15]. Like-
wise, in a study conducted in rural India, TC levels at
both 18 and 28 weeks gestation were associated with
higher infant birth weight [16]. These findings are con-
sistent with the high demand for cholesterol during
pregnancy to meet both maternal and fetal needs [10].
Although the primary source of cholesterol for the fetus
may be derived from fetal biosynthesis, recent studies
demonstrated that placental trophoblast and endothelial
cells can effectively transfer maternal cholesterol to the
fetus throughout pregnancy, thus impacting on fetal
growth and infant birth weight [29–31].
Similar to our findings of an association between low
HDL-c in the second trimester and greater risk of LBW,
a study conducted in the US (n = 1207) reported that
low HDL-c measured at 16–27 weeks gestation was asso-
ciated with a lower birth weight [12]. Low HDL-c levels
in non-pregnant populations have been associated with
atherogenic lipid profiles and higher risks of cardiovas-
cular disease and mortality [32–34]. During pregnancy,
low HDL-c levels have been linked to greater risks of
adverse pregnancy outcomes [35], including preterm
birth [36], a shorter pregnancy length [27] and pre-
eclampsia [35, 37]. One of the main functions of HDL is
to promote reverse cholesterol transport from peripheral
tissues to the liver for excretion in bile acids. Since HDL
presents anti-atherogenic and anti-inflammatory proper-
ties, a low level of HDL-c during pregnancy may in-
crease the risk of endothelial damage in uteroplacental
and fetal tissues caused by inflammation resulting in pla-
cental dysfunction, inadequate supply of oxygen and nu-
trients to the fetus and intrauterine growth restriction
(IUGR) [38, 39].
Additionally, at 30 weeks gestation, we detected associ-
ations between high LDL-c and reduced risk of SGA and
between increased LDL-c levels and higher infant birth
weight. This corroborates the findings of a study con-
ducted in Scotland (n = 66) which reported an associ-
ation between low LDL-c in the first trimester and
IUGR [40]. Studies in both animal models and human
subjects suggest that fetal growth is supported by the
uptake of maternal cholesterol from the circulation by
the placenta via various receptors including VLDL and
LDL receptors [31, 41, 42]. Therefore, increased mater-
nal LDL-c levels during pregnancy may promote fetal
growth and higher infant birth weight.
In accord with previous research, our data show that
at 30 weeks gestation women with high TG delivered in-
fants who were on average 122 g heavier than those born
to women with referent TG values. And, women with
SGA infants had lower mean TG levels compared to
those with AGA infants. Notably, Kulkarni et al. re-
ported that a one SD higher TG level at 28 weeks gesta-
tion was associated with a 36 g higher birth weight [16]
Table 7 Mean differences in birth weight by percentile groups of maternal total, HDL and LDL cholesterol and triglycerides levels, at
enrolment, 20 and 30 weeks gestationa (Continued)
Gestation week mg/dL N Unadjusted Adjustedb
Mean difference (95% CI)
in birth weight (g)
p-value Mean difference (95% CI)
in birth weight (g)
p-value
Ref (10th─90th) 35.4─88.6 424 Ref Ref
High (>90th) > 88.6 54 41.7 (−77.8, 161.2) 0.493 34.9 (−96.6, 166.3) 0.602
20 weeks Ref
Low (<10th) < 53.1 57 28.5 (−72.3, 129.3) 0.578 26.5 (−79.6, 132.5) 0.624
Ref (10th─90th) 53.1─112.5 361 Ref Ref
High (>90th) > 112.5 47 89.6 (−21.5, 200.6) 0.114 59.6 (−54.3, 173.5) 0.304
30 weeks
Low (<10th) < 65.5 48 28.5 (−70.3, 127.3) 0.571 21.0 (−89.5, 131.5) 0.709
Ref (10th─90th) 65.5─134.6 409 Ref Ref
High (>90th) > 134.6 51 126.5 (25.0, 227.9) 0.015 121.8 (5.2, 238.4) 0.041
aMaternal lipid levels were divided by percentile groups; <10th percentile (low), 10th─90th (reference, Ref), >90th percentile (high)
bAdjusted mean birth weight with maternal age, parity, gestational age, hemoglobin concentration, BMI, supplement group, and compliance to supplement
during pregnancy, and infant birth sex and birth season
cMean (SD) gestational age at enrolment was 13.9 (3.3) weeks gestation
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein
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and Jin et al. reported that increased TG levels in the
third trimester were associated with a reduced risk of
SGA [10]. However, contrary to studies conducted in
populations with greater rates of overweight and obesity
[12, 17, 19, 43], our data suggests a limited impact of
TG on birth weight-related outcomes, which may be
linked to the lower levels of TG detected in this cohort
and may reflect poor dietary intake of TG [36, 44–46].
Maternal TG and their derived non-esterified fatty acids
(NEFA) are mainly obtained through maternal diet and
their levels during pregnancy have been shown to dir-
ectly correlate with fetal lipid levels and fetal growth,
thereby impacting birth weight [47].
Although all LBW infants were also born SGA in our
study, the results show differences in the relationships be-
tween maternal lipids during pregnancy and the risks of
LBW and SGA. While increased HDL-c or TC levels in
the first half of pregnancy were linked to a reduced risk of
LBW, high LDL-c or TG at 30 weeks gestation were re-
lated to a reduced risk of SGA. This suggests that the
pathophysiological mechanisms linking gestational lipid
levels to the risk of LBW may arise early in gestation, dur-
ing the anabolic phase of pregnancy characterized by an
accumulation of fat in maternal adipose tissue [48]. Inad-
equate levels of anti-atherogenic and anti-inflammatory
molecules (i.e. HDL) during this phase may cause lipid ob-
struction of vascular tissues and inflammation resulting in
a cascade of events leading to LBW. Maternal inflamma-
tion during pregnancy has been associated with IUGR in a
study conducted in rural Nepal (n = 653) [49] and with
lower birth weight in a cohort (n = 144) from Tanzania
[50]. In contrast, the pathophysiological mechanisms asso-
ciated with the risk of SGA may appear later in pregnancy;
during the catabolic phase where insulin resistance and
placental hormones induce the release of free fatty acids
from maternal adipose tissue to meet the heightened fetal
energy demands. Low pregnancy weight gain may cause
insufficient storage of energy in adipose tissue and supply
of cholesterol or TG to the fetus during the catabolic
phase of pregnancy. This may reduce fetal growth and re-
sult in an infant born SGA. Inadequate weight gain during
the third trimester has been linked to IUGR and SGA in a
study conducted in rural Bangladesh (n = 1463) [51]. Al-
tered adipose tissue and reduced body fat mass have been
reported in infants born SGA compared to those born
AGA or LGA [52, 53].
Maternal undernutrition during pregnancy causes meta-
bolic stresses which may adversely impact on fetal growth
and birth outcomes. In this study and others, underweight
women were found more likely to have an LBW or SGA
infant compared to women with a normal weight [48–51].
Furthermore, our results show that although maternal nu-
tritional supplementation with a lipid-based supplement
(PE or PE +MMN) during pregnancy was associated with
altered lipid levels, no direct associations were observed
between maternal supplement groups and birth weight
outcomes. This may indicate a limited effect of supple-
mentation during pregnancy and a greater role of mater-
nal weight on infant birth weight outcomes in this cohort
[54].
The major strengths of this study include the use of a
large cohort from a population in rural sub-Saharan Af-
rica, bringing new perspectives into the relationships be-
tween maternal lipids and infant birth outcomes in
populations where the burden of LBW and SGA is the
highest and where research findings are limited. The mea-
surements of maternal plasma TC, HDL-c, LDL-c, and
TG levels at three-time points across pregnancy allow a
greater understanding of the adaptive process through
which maternal lipids impact on fetal growth. The assess-
ment of potential associations using maternal lipid levels
as continuous variables and percentile groups with or
without adjustment with confounding factors allowed a
robust and thorough analysis of the links between gesta-
tional lipids and birth weight-related outcomes.
Limitations of this study should be noted, and caution
should be taken in the interpretation of the results. This
study is a secondary analysis of a clinical trial of nutri-
tional supplementation which by its observational design
precludes any conclusion on causal links between mater-
nal lipid levels and infant’s size at birth. Pregnant
women in our study were healthy, had a singleton infant
and received supplementation and comprehensive ante-
natal care throughout pregnancy, and therefore may not
be representative of all eligible Gambian women. A fur-
ther limitation of the trial design was the lack of data or
samples from late pregnancy to allow lipid measure-
ments after 30 weeks gestation. Such data may have con-
tributed to the understanding of the relationships
between gestational lipids and birth outcomes.
Conclusions
In conclusion, our data from rural sub-Saharan Africa indi-
cate that maternal plasma lipid levels during pregnancy
may influence fetal growth, thereby impacting on birth
weight and the risks of LBW and SGA. Importantly, our
findings suggest that distinct pathophysiological pathways
may be involved in the relationships between maternal lipid
levels during pregnancy and LBW and SGA outcomes, with
differential effects according to the lipid component and
the stage of gestation. Additionally, in this cohort of pri-
marily subsistence farming women, underweight women
were found at greater risk of having an LBW or SGA infant,
highlighting the critical role of maternal nutritional status
on birth weight outcomes. Thus, our study supports inter-
ventions that monitor and optimize maternal lipid levels
across pregnancy while promoting an adequate gestational
weight gain.
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